P53 Status Influences the Anti-proliferative Effect Induced by IFITM1 Inhibition in Estrogen Receptor-positive Breast Cancer Cells

被引:1
作者
Sun, Der Sheng [1 ]
Yoon, Jung-Sook [2 ]
Kim, Yong-Seok [3 ]
Won, Hye Sung [1 ]
机构
[1] Catholic Univ Korea, Coll Med, Dept Internal Med, Seoul, South Korea
[2] Catholic Univ Korea, Uijeongbu St Marys Hosp, Coll Med, Clin Res Lab, Uijeongbu St, Seoul, South Korea
[3] Catholic Univ Korea, Coll Med, Dept Surg, Seoul, South Korea
基金
新加坡国家研究基金会;
关键词
Breast cancer; tamoxifen; interferon-induced transmembrane protein 1; P53; GENES;
D O I
10.21873/cgp.20468
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Background/Aim: Interferon-induced trans- membrane protein 1 (IFITM1) is known to be involved in breast cancer progression. We aimed to investigate its role in estrogen receptor (ER)-positive breast cancer cells with wild- type p53 and tamoxifen-resistant breast cancer cells. Materials and Methods: The ER-positive breast cancer cell lines, MCF7 with wild-type p53 and T47D with mutant p53, were used. We established an MCF-7-derived tamoxifen-resistant cell line (TamR) by long-term culture of MCF-7 cells with 4hydroxytamoxifen. Results: IFITM1 inhibition in MCF-7 cells significantly decreased cell growth and migration. MCF-7 cells with suppression of IFITM1 using siRNA or ruxolitinib showed reduced cell viability after tamoxifen treatment compared with that in the control MCF-7 cells. Unexpectedly, mRNA and protein levels of IFITM1 were decreased in TamR cells compared with those in MCF-7 cells. TamR cells with suppression of IFITM1 using siRNA or ruxolitinib showed no change in cell viability after treatment with tamoxifen. P53 knockdown using siRNA reduced the mRNA levels of IRF9 and increased mRNA and protein levels of SOCS3 in MCF-7 cells, suggesting that loss or mutation of p53 can affect the induction of IFITM1 via the JAK/STAT signaling pathway in breast cancer. Furthermore, MCF-7 cells with p53 knockdown using siRNA showed no decrease in cell viability after tamoxifen treatment or IFITM1 inhibition, indicating that p53 status may be important for cell death after tamoxifen treatment or IFITM1 inhibition. Conclusion: IFITM1 inhibition may enhance the sensitivity to tamoxifen based on p53-dependent enhancement of IFN signaling in wild-type p53, ER-positive breast cancer cells.
引用
收藏
页码:511 / 522
页数:12
相关论文
共 50 条
[41]   SIRT1 deacetylase is overexpressed in human melanoma and its small molecule inhibition imparts anti-proliferative response via p53 activation [J].
Wilking, Melissa J. ;
Singh, Chandra ;
Nihal, Minakshi ;
Zhong, Weixiong ;
Ahmad, Nihal .
ARCHIVES OF BIOCHEMISTRY AND BIOPHYSICS, 2014, 563 :94-100
[42]   Anti-tumorigenic effects of a novel digitoxin derivative on both estrogen receptor-positive and triple-negative breast cancer cells [J].
Kulkarni, Yogesh M. ;
Yakisich, Juan S. ;
Azad, Neelam ;
Venkatadri, Rajkumar ;
Kaushik, Vivek ;
O'Doherty, George ;
Iyer, Anand Krishnan V. .
TUMOR BIOLOGY, 2017, 39 (06)
[43]   CDK9 inhibitors selectively target estrogen receptor-positive breast cancer cells through combined inhibition of MYB and MCL-1 expression [J].
Mitra, Partha ;
Yang, Ren-Ming ;
Sutton, James ;
Ramsay, Robert G. ;
Gonda, Thomas J. .
ONCOTARGET, 2016, 7 (08) :9069-9083
[44]   Additive antitumor effect of concurrent treatment of 4-hydroxy tamoxifen with 5-fluorouracil but not with doxorubicin in estrogen receptor-positive breast cancer cells [J].
Junichi Kurebayashi ;
Mamoru Nukatsuka ;
Hideki Nagase ;
Tsunehisa Nomura ;
Mai Hirono ;
Yutaka Yamamoto ;
Yoshikazu Sugimoto ;
Toshinori Oka ;
Hiroshi Sonoo .
Cancer Chemotherapy and Pharmacology, 2007, 59 :515-525
[45]   Additive antitumor effect of concurrent treatment of 4-hydroxy tamoxifen with 5-fluorouracil but not with doxorubicin in estrogen receptor-positive breast cancer cells [J].
Kurebayashi, Junichi ;
Nukatsuka, Mamoru ;
Nagase, Hideki ;
Nomura, Tsunehisa ;
Hirono, Mai ;
Yamamoto, Yutaka ;
Sugimoto, Yoshikazu ;
Oka, Toshinori ;
Sonoo, Hiroshi .
CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2007, 59 (04) :515-525
[46]   Interaction Between MUC1 and STAT1 Drives IFITM1 Overexpression in Aromatase Inhibitor-Resistant Breast Cancer Cells and Mediates Estrogen-Induced Apoptosis [J].
Escher, Taylor E. ;
Lui, Asona J. ;
Geanes, Eric S. ;
Waller, Katherine R. ;
Tawfik, Ossama ;
Hagan, Christy R. ;
Lewis-Wambi, Joan .
MOLECULAR CANCER RESEARCH, 2019, 17 (05) :1180-1194
[47]   Potent anti-proliferative effects of metformin on trastuzumab-resistant breast cancer cells via inhibition of ErbB2/IGF-1 receptor interactions [J].
Liu, Bolin ;
Fan, Zeying ;
Edgerton, Susan M. ;
Yang, XiaoHe ;
Lind, Stuart E. ;
Thor, Ann D. .
CELL CYCLE, 2011, 10 (17) :2959-2966
[48]   Disruption of estrogen receptor α-p53 interaction in breast tumors: a novel mechanism underlying the anti-tumor effect of radiation therapy [J].
Wensheng Liu ;
Margot M. Ip ;
Matthew B. Podgorsak ;
Gokul M. Das .
Breast Cancer Research and Treatment, 2009, 115 :43-50
[49]   Disruption of estrogen receptor α-p53 interaction in breast tumors: a novel mechanism underlying the anti-tumor effect of radiation therapy [J].
Liu, Wensheng ;
Ip, Margot M. ;
Podgorsak, Matthew B. ;
Das, Gokul M. .
BREAST CANCER RESEARCH AND TREATMENT, 2009, 115 (01) :43-50
[50]   Hormone receptor status (estrogen receptor, progesterone receptor), human epidermal growth factor-2 and p53 in South Indian breast cancer patients: A tertiary care center experience [J].
Patnayak, Rashmi ;
Jena, Amitabh ;
Rukmangadha, Nandyala ;
Chowhan, Amit Kumar ;
Sambasivaiah, K. ;
Phaneendra, Bobbit Venkatesh ;
Reddy, Mandyam Kumaraswamy .
INDIAN JOURNAL OF MEDICAL AND PAEDIATRIC ONCOLOGY, 2015, 36 (02) :117-122